B-cell Activating Factor
TNFSF13BproteinBAFF, released from activated platelets, amplifies B-cell and vascular inflammation in atherothrombotic coronary disease.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationalePlatelet-derived proatherogenic marker; TNF superfamily; links adaptive immunity and platelet activation.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates7
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000102524
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I37
C — confounder / Type-II59
A — assay feasibility72
E — evidence strength22
T1DI (composite)6
Specificity differential (R−C)-21.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Microvesicles in plasma reflect coronary flow reserve in patients with cardiovascular disease.American journal of physiology. Heart and circulatory physiology · 2021 · PMID 33797274 · doi